Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

12.74
-0.0900-0.70%
Volume:490.53K
Turnover:6.08M
Market Cap:1.06B
PE:-4.02
High:12.77
Open:12.69
Low:12.07
Close:12.83
52wk High:19.11
52wk Low:3.91
Shares:83.43M
Float Shares:59.91M
Volume Ratio:0.55
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1700
EPS(LYR):-3.1667
ROE:-72.19%
ROA:-38.89%
PB:3.47
PE(LYR):-4.02

Loading ...

EyePoint doses first patients in Phase 3 DURAVYU trials for diabetic macular edema

Reuters
·
Mar 02

EyePoint Inc: Topline Data for Duravyu in Dme Anticipated in 2H 2027

THOMSON REUTERS
·
Mar 02

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of Duravyu™ for the Treatment of Diabetic Macular Edema

THOMSON REUTERS
·
Mar 02

EyePoint Inc. to Report Fourth-Quarter and Full-Year Financial Results on Conference Call

Reuters
·
Feb 25

EyePoint management to participate in upcoming investor conferences

Reuters
·
Feb 24

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities

TIPRANKS
·
Feb 24

EyePoint Chief Medical Officer Ramiro Ribeiro Disposes of Common Shares

Reuters
·
Feb 19

EyePoint Names Michael Campbell Chief Commercial Officer

Reuters
·
Feb 18

EyePoint Appoints Michael Campbell as Chief Commercial Officer

THOMSON REUTERS
·
Feb 18

BRIEF-Eyepoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Feb 17

EyePoint Grants Stock Options to New Employees as Inducement Awards

Reuters
·
Feb 17

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 17

EyePoint Inc. nimmt am Guggenheim Emerging Outlook: Biotech Summit teil

Reuters
·
Feb 05

EyePoint Grants Stock Options to New Employees as Inducement Awards

Reuters
·
Jan 16

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 16

EyePoint Pharmaceuticals: Advancing DURAVYU Phase 3 Programs with Strong Cash Runway Supports Buy Rating and $23 Target

TIPRANKS
·
Jan 08

EyePoint Inc. Chief Medical Officer Ramiro Ribeiro Reports Disposal of Common Shares

Reuters
·
Jan 08

EyePoint Inc. to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 07

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

GlobeNewswire
·
Jan 07